Integrin α-V
| Integrin alpha-V | ||
|---|---|---|
|
||
| according to PDB 1JV2 | ||
| other names |
Vitronectin receptor subunit alpha, CD antigen: CD51 |
|
| Properties of human protein | ||
| Mass / length primary structure | 1,048 amino acids , 116,038 Da | |
| Identifier | ||
| Gene name | ITGAV | |
| External IDs | ||
| Orthologue (human) | ||
| Entrez | 3685 | |
| Ensemble | ENSG00000138448 | |
| UniProt | P06756 | |
| Refseq (mRNA) | NM_001144999.2 | |
| Refseq (protein) | NP_001138471.1 | |
| PubMed search |
3685
|
|
Integrin α-V (CD51) is a surface protein from the group of integrins .
properties
Integrin α-V is a cell adhesion molecule and binds to the RGD sequence as well as vitronectin , cytotactin , fibronectin , fibrinogen , laminin , matrix metalloproteinase-2 , osteopontin , osteomodulin , prothrombin , thrombospondin and the von Willebrand factor . It's glycosylated . Integrin α-V forms a heterodimeric receptor with integrin beta-3 for fractalkin , FGF-1 , IGF-1 , and NRG1 . Furthermore, it binds PLA2G2A at a different binding site, which increases the affinity for binding other ligands . The receptor consisting of integrin alpha-V and integrin beta-3 as well as the complex consisting of integrin alpha-V and integrin beta-6 bind fibrillin-1 and are thus involved in cell adhesion .
The adenovirus of type C used the complex of the integrin α-V and integrin beta-5 as a receptor. Coxsackieviruses of types A9 and B1 use the complex of integrin α-V and either integrin beta-3 or integrin beta-5 as a receptor. The HHV-8 , the West Nile virus and the human Parechovirus 1 using the complex of the integrin α-V and integrin beta-3 as the receptor.
The antibodies abituzumab and intetumumab bind to integrin α-V.
Web links
Individual evidence
- ↑ E. Elez, I. Kocáková, T. Hohler TO Martens, C. Bokemeyer, E. Van Cutsem, B. Melichar, M. Smakal, T. Csőszi, E. Topuzov, R. Orlova, S. Tjulandin, F Rivera, J. Straub, R. Bruns, S. Quaratino, J. Tabernero: Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with wild-type metastatic colorectal cancer: the randomized phase I / II POSEIDON trial. In: Annals of Oncology. 26, 2014, p. 132, doi : 10.1093 / annonc / mdu474 .